Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
1.350
-0.110 (-7.53%)
Jul 29, 2025, 4:00 PM - Market closed
Tharimmune Employees
As of December 31, 2024, Tharimmune had 3 total employees, including 2 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$4,161,054
Market Cap
5.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | 0 | - |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
THAR News
- 6 days ago - Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants - Accesswire
- 6 weeks ago - Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors - Accesswire
- 3 months ago - Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback - Accesswire
- 3 months ago - Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences - Accesswire
- 3 months ago - Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors - Accesswire
- 3 months ago - Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback - Accesswire
- 3 months ago - Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - Accesswire
- 4 months ago - Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Accesswire